Divis Laboratories Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/y6w9232bz8rw8oaghsc1x2gn.pdf

Key Takeaways


Custom Synthesis: The Growth Engine

Dr. Kiran S. Divi: "It's not something that we started after China Plus One or the Biosecure Act has started, our business was there. We've been in this business even before anyone has ever been in it."

Kakinada: Supply Security First, Margin Later

Dr. Kiran S. Divi: "Kakinada more than creating space or controlling our price, the main reason of having Kakinada is for having continuous supply of our own raw materials and our critical starting materials."

Generic Business: Volume Resilience Under Price Pressure

Dr. Kiran S. Divi: "See, as of now, I am bound by confidentiality. It is whether I am producing for innovator, I mean, based on our knowledge, knowhow and everything, we believe we are best suited now to work on innovative molecules in the GLP space."

Peptides & New Modalities: Building Before the Boom


Margins & Supply Chain: Favorable but Fragile

Nilima Prasad Divi: "But if you ask me what my wishful thinking is, I would love to maintain a lean inventory. I wouldn't want to have lot of inventory stocks, I would definitely want to have a lean inventory wherein I can implement more of just in time and have it just source what I am manufacturing at that point in time."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthDouble-digit growth for the organization overallFY26 and next few years
New CS project commercializationTwo projects (₹700-800 crores CAPEX) commercialized, subject to customer regulatory approvalsLate 2026 or early 2027
Kakinada Phase-I completion~₹200 crores remaining CAPEX to be spentNot specified
Annual CAPEX~₹1,400 crores plus maintenance CAPEX, mainly for projects announced this financial yearFY26
Favorable procurement environmentContinued price and supply stability expectedNext two quarters
Sea freight ratesBroadly stableQ1 FY26

Key Metrics

MetricQ4 FY25
Consolidated total income₹2,671 cr, vs ₹2,382 cr in Q4 FY24
Profit before tax₹864 cr, vs ₹713 cr in Q4 FY24
Profit after tax₹662 cr, vs ₹538 cr in Q4 FY24
Forex gain₹10 cr gain, vs ₹2 cr loss in Q4 FY24
Material consumption~40% of sales revenue, flat YoY
Constant currency growth (FY25)18%, vs negative 2% in FY24
Export share of total sales (FY25)~88%
Europe and US share of total sales (FY25)73%, vs 70% in FY24
Product mix: Generics vs Custom Synthesis49% / 51%
Nutraceutical revenue₹205 cr for the quarter; ₹781 cr for FY25
Assets capitalized in the quarter₹560 cr, of which Kakinada project: ₹337 cr
Capital work-in-progress₹1,022 cr, of which Kakinada project: ₹562 cr
Total spent on Kakinada project to date₹1,497 cr (including assets capitalized and advances)
Cash on books₹3,696 cr
Receivables₹2,855 cr
Inventory₹3,033 cr
Other expenses as % of sales (FY25)14%, down from 17% in FY24
EBITDA margin (FY25)32%, up from 29% in FY24
Revenue growth guidance (FY26)Double-digit growth
CAPEX planned for FY26~₹1,400 cr plus maintenance CAPEX
Kakinada Phase-I additional CAPEX planned~₹200 cr
Commercialization timeline for new CS projectsLate 2026 to early 2027, subject to regulatory approvals